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(TCD-BM) was transplanted in combination with untreated, ﬂudara-
bine-treated, 7.5Gy -irradiated, or PUVA-treated splenocytes. GvL
activity was studied by administering a lethal number of H2k T
lymphoma cells (LBRM) or H2b myeloid lymphoma cells (C1498).
Post-transplant survival of recipient groups was determined, and
GvHD and GvL effects were assessed by clinical and pathological
scoring. Hematopoietic chimerism and donor T cell expansion were
analyzed by ﬂow cytometric analysis of peripheral blood samples at
days 30 and 60 post-BMT. In addition, the short-term in vitro survival
of memory and naive donor T cell subsets was monitored after
ﬂudarabine, PUVA, or -irradiation. Results: In vitro survival of all
donor T cell subsets 2 days after -irradiation or PUVA was minimal,
while ﬂudarabine-treated T cells demonstrated preferential survival of
memory T-cells. Allogeneic splenocytes treated with ﬂudarabine,
7.5Gy -irradiation, or PUVA had signiﬁcantly diminished GvHD
activity compared to untreated donor splenocytes, and facilitated en-
graftment of low-dose TCD-BM. Fludarabine-treated splenocytes
(and PUVA-treated, to a lesser extent) retained GvL activity and
contributed more to donor T cell engraftment compared to -irradi-
ated donor splenocytes. The results are consistent with other studies
suggesting that donor memory T-cells contribute to GvL activity but
do not produce GvHD.Conclusions: Among ex vivo methods tested
that inhibited GvHD activity of allogeneic lymphocytes, ex vivo treat-
ment with ﬂudarabine is superior to -irradiation or PUVA, resulting
in better separation of GvHD and GvL activities in murine models of
allogeneic BMT.
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REVEALING KINETICS OF CYTOKINE INDUCED KILLER CELL TRAFFICK-
ING AND SURVIVAL IN VIVO
Nishimura, R., Baker, J., Beilhack, A., Wieland, C.B., Negrin, R.S.
The Division of Bone and Marrow Transplantation, Department of
Medicine, Stanford University School of Medicine, Stanford, CA.
Cytokine induced killer cells (CIK), which are generated from
splenocytes in mice and PBMC in human by the timed addition of
IFN-, anti-CD3 MAbs and IL-2, express both T cell and NK cell
markers. CIK cells kill tumors through NKG2D mediated cyto-
toxicity and have in vivo activity in several murine models. CIK
cells have been utilized in the clinic after both auto and allo
transplant to treat or possibly reduce the risk of disease recurrence.
Our goal was to explore CIK kinetics in vivo in the absence of
exogenous cytokines. To this end, we transplanted luciferase-la-
beled murine CIK cells to compare the trafﬁcking patterns in
different transplant settings (syngeneic vs allogeneic, and myeloa-
blative vs nonmyeloablative) and identiﬁed the survival time of
CIK cells in each BMT setting by in vivo bioluminescence imaging
(BLI). BLI studies showed that CIK cells were proliferated rapidly
in secondary lymphoid organs such as the spleen, cervical and
mesenteric lymph nodes. This observation was similar to the pat-
tern of fresh splenocyte administration. In contrast, severe acute
GVHD was not observed even in CIK dose escalation studies. CIK
cell derived signals were detected more than 80 days after BMT.
Moreover to clarify which lymphocyte subpopulations mainly pro-
liferate in vivo, we also transplanted CIK cells generated from GFP
positive splenocytes and sequentially analyzed tissue distribution.
We conﬁrmed that GFPCD8NKG2D cells expanded in vivo
in allogeneic BMT models. In contrast, syngeneic CIK cells did
not home to any speciﬁc organs and proliferated much less com-
pared to those of allogeneic CIK cells, but GFP positive cells were
detected for at least 21 days after transplantation. We demon-
strated that the kinetics of CIK cell survival was different among
each BMT setting and CIK cells could survive without the addition
of exogenous cytokines in vivo for prolonged periods, especially in
allogeneic BMT settings.
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IMPACT OF ALLOGENEIC SIBLING DONOR-DERIVED PRE-TRANSPLAN-
TATION CD16/56CD3 CELLS
Kim, H.-J.1, Choi, Y.1, Jeong, H.-Y.1, Min, W.-S.1, Kim, S.-Y.1,
Eom, K.-S.1, Lee, S.1, Min, C.-K.1, Cho, S.-G.1, Lee, J.-W.1,
Kim, C.-C.1, Kim, T.-G.2 1. Catholic HSCT Center, St Mary’s Hos-
pital, Catholic Univ of Korea College of Medicine, Seoul, Republic of
Korea; 2. Dept of Microbiology, Catholic Univ of Korea College of
Medicine, Seoul, Republic of Korea.
The associations between the numbers of donor-derived pre-
transplantation CD16/56CD3 cells and clinical outcome were
investigated. Blood samples were obtained from 41 adult HLA-
matched sibling donors on the day of transplantation. The median
percentage of CD16/56 cells recovered from the total MNCs of
the donors was 8.5% (range, 0.9–27%). In addition, the median
percentage of CD16/56CD3 cells from these populations was
3.2% (range, 0.1–10.6%). Patients who received high levels of
donor CD16/56CD3 cells showed more favorable outcomes.
The numbers of donor CD16/56CD3 cells were associated
with the development of acute GVHD (P  .028) and chronic
GVHD (P .0318), suggest a trend towards an inverse correlation
between the numbers of CD16/56CD3 cells and the incidence
of GVHD. The numbers of donor CD16/56CD3 cells in
association with the disease-free survival were not statistically sig-
niﬁcant (P  .0943). However, the higher numbers of donor
CD16/56CD3 cells infused showed signiﬁcantly lower rates of
transplant-related complications (TRC) (P  .02). These results
suggest that the levels of donor CD16/56CD3 cells may be an
evaluable parameter to consider when performing allogeneic he-
matopoietic stem cell transplantation in terms of limiting the
chances of TRC, including GVHD or relapse.
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SELECTIVE DOWNREGULATION OF ALLOREACTIVITY IN A HUMAN
MODEL OF EXTRACORPOREAL PHOTOTHERAPY TREATMENT OF
GRAFT-VERSUS-HOST DISEASE
Marshall, S.R., Wang, X.N., Dickinson, A.M. Haematological Sciences,
University of Newcastle Upon Tyne, Newcastle Upon Tyne, Tyne &
Wear, United Kingdom.
Graft-versus-host disease (GvHD) remains the most serious
complication following haemopoietic stem cell transplantation,
with an incidence of 40-60% and can be fatal in up to 50% of cases.
Extracorporeal phototherapy (ECP) is a novel treatment of both
acute and chronic GvHD involving psoralen and UVA (PUVA)
treatment of peripheral blood cells with high reported success even
in those resistant to conventional immunosuppressive treatments.
ECP appears to induce selective immune suppression without
increased rates of infection or disease relapse, but its mechanism of
action remains poorly understood. In our department the human
skin explant model for GvHD has been shown to be highly pre-
dictive of clinical GvHD and has been used to investigate the
pathophysiology of the disease. The model involves sensitizing
donor lymphocytes with recipient lymphocytes in vitro in a pri-
mary mixed lymphocyte reaction and then evaluating the second-
ary response on recipient skin biopsies by grading the graft versus
host reactivity (grades I–IV) histopathologically using the Lerner
grading system for GvHD. ECP only treats a small proportion of
circulating mononuclear cells at each visit, but is able to down-
regulate GvHD through effects on untreated cells. Similarly in the
skin explant model, Graft-versus-host reactivity of untreated cells
was inhibited in 11 out of 19 (P  .007) experiments by combining
the untreated cells with PUVA treated cells. Investigation of the
mechanism of this downregulation of alloreactivity revealed inhi-
bition of T cell proliferation with a dose response dependent upon
the ratio of PUVA treated cells to untreated cells. Furthermore
downregulation of T cell proliferation only occurred when PUVA
treatment was performed on sensitized responder cells. Treatment
of naive cells caused minimal or no inhibition. This selective
downregulation of an alloresponse has previously been shown in
mice, but this is the ﬁrst demonstration of the selective action in a
human system. Initial experiments have also shown that combining
PUVA treated and untreated sensitized cells results in downregu-
lation of cell-mediated cytotoxicity. This unique human model of
ECP will allow investigation of cell-mediated and soluble factor
changes associated with PUVA treatment of mononuclear cells and
thus enable us to better understand the mechanism of action of
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ECP in the treatment of GvHD. Better understanding of the
mechanism is crucial for reﬁning the use of this novel therapy.
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EXTRACORPOREAL PHOTOCHEMOTHERAPY (ECP) IN PATIENTS WITH
ACUTE OR CHRONIC GRAFT VERSUS HOST DISEASE (a/cGVHD): CLIN-
ICAL AND IMMUNOLOGICAL OUTCOME
Cristina, T.1, Mario, A.2, PierLuigi, T.1, Arcangelo, P.3, Valeria, G.1,
Anna, N.1, Roberto, C.1 1. Servizio di Immunoematologia e Medicina
Trasfusionale-Policlinico Sant’Orsola-Malpighi, Bologna, Italy; 2. Isti-
tuto di Ematologia ed Oncologia Medica “Seragnoli”-Policlinico
Sant’Orsola-Malpighi, Bologna, Italy; 3. Clinica Pediatrica-Policlinico
Sant’Orsola-Malpighi, Bologna, Italy.
ECP may improve clinical status in acute or chronic GVHD
patients refractory to several lines of immunosuppression. From
September 2003, 12 patients, 2 pediatric (1c and 1 aGVHD) and 10
adults (9c and 1 aGVHD) were admitted to ECP courses. To date,
8/12 are evaluable. Three steps ECP procedures were performed:
a mean of 15,6 (10–54) ECP were carried out per patient, mean
treatment duration was 4,8 (1,5–18) months. Acute GVHD pa-
tients underwent ECP within 1 month from the onset, whereas the
delay was signiﬁcantly longer in cGVHD patients: 12,5 (12–16)
months. An intensive treatment was applied to maintain clinical
improvement during the tapering of the immunosuppressive ther-
apy. Haematological parameters were studied before every ECP.
Monthly, cytoﬂuorimetric analysis was carried out to detect the
CD4, CD8, CD4CD25, NK subsets, CD19 B lympho-
cytes, and VB TCR oligoclonal subpopulations. 8/8 patients
showed skin GVHD manifestations, 5/8 liver function impairment,
3/8 oral lichen, and 2/8 mild ocular GVHD. Signiﬁcant skin
improvement was observed in 6/8 patients while a partial liver
recovery was detectable in 1/5, oral lichen remained stable in 2/3
patients. Moderate lymphopenia, in particular due to the decreas-
ing in CD8 subset, was observed in 4/8 patients. Oligoclonal
expansion of some subfamilies as VB14 (5/8), VB5.1 (4/8), VB20
(3/8), and VB16 (2/8) was found in overall patients. Fast disappear-
ance of these T subsets seemed to correlate with initial response
rate to ECP, but the same subsets were not detectable in 2 patients
that had become ECP resistant. Absolute ECP-treated and rein-
fused T lymphocytes did not seem relevant to ECP response, as 0,6
(0,2-3) and 0,75 (0,2-2)x10E8/KG lymphocytes were respectively
reinfused in responsive and resistant patients. ECP procedures
were well tolerated without relevant side effects. In conclusion,
response to ECP was satisfactory in 6/8 patients with skin GVHD,
while, as expected from already published series of patients, low
response rate was observed in liver, ocular and oral disease.
Though our case-study is limited, a more intensive ECP schedule
and prolonged time of treatment, once a clinical improvement has
been obtained, might be useful to maintain the reached results.
However, ECP might be performed in more selected patients, in
particular in skin GVHD patients.
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RNA TRANSFECTED CORD BLOOD-DERIVED DENDRITIC CELLS GENER-
ATE ANTI-LEUKEMIC CYTOTOXIC T LYMPHOCYTES
Hsu, A.K.1, Kerr, B.M.1, Lock, R.B.2, Hart, D.N.1, Rice, A.M.1 1Mater
Medical Research Institute, South Brisbane, Queensland, Australia;
2Children’s Cancer Institute Australia, Randwick, New South Wales,
Australia.
Acute Lymphocytic Leukaemia (ALL) patients who relapse after
haematopoietic stem cell transplantation have few therapeutic op-
tions. An immunotherapeutic approach that enhances the graft
versus leukemia effect may improve their survival. We postulate
that cord blood (CB) CD34-derived dendritic cells (DC) will be
ideal source of DC for CB transplant recipients. In addition, we
propose using RNA as a source of antigen to induce T cell re-
sponses to poorly immunogenic tumors such as ALL. CD34 cells
can expand and differentiate into DC and function as professional
antigen presenting cells. We regularly achieve 	90% transfection
efﬁciency with 	90% cell viability when CD34-DC are electro-
porated with eGFP mRNA. Electroporation of CD34-DC with
ﬂu mRNA results in processing, translation and presentation of
epitopes by the DC, and killing by ﬂu-speciﬁc Cytotoxic T Lym-
phocytes (CTL). We have induced CTL using leukemic total RNA
from the HLA-A2 ALL Nalm-6 cell line. The CTL speciﬁcally
lysed 49 11% of Nalm-6 cells compared to less than 7% lysis of
autologous and allogeneic mononuclear cells (P  .03 and P 
.022, respectively). Interestingly, CTL generated from Nalm-6
total RNA were also able to lyse 16 5.4% of autologous survivin
mRNA transfected DC. CTL cultures consisted of 70% CD4 and
10–15% CD8 with less than 10% NK cells. To test the in vivo
efﬁcacy of these anti-leukemic CTL, we have established a NOD-
SCID mouse model of ALL from patient samples. By varying the
inocula of ALL cells, we have established a model of emerging
relapse. The consistent and predictable engraftment rates post
transplant will allow us to administer CTL at different time points
in vivo to test the efﬁcacy of the CTL at controlling in vivo
leukemic growth.
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PROPHYLAXIS OF GRAFT-VERSUS-HOST DISEASE (GVHD) WITH TA-
CROLIMUS AND METHOTREXATE AFTER ALLOGENEIC BONE MARROW
TRANSPLANTATION (BMT) FROM UNRELATED DONOR: IMPACT OF
BLOOD LEVEL OF TACROLIMUS ON THE DEVELOPMENT OF ACUTE
GVHD
Mori, T., Nakazato, T., Aisa, Y., Yamazaki, R., Ikeda, Y., Okamoto, S.
Division of Hematology, Keio University School of Medicine, Tokyo,
Japan.
Background: Although tacrolimus has been widely used for the
prophylaxis of GVHD, its optimal target blood level has not been
fully elucidated. This is a prospective single institute study evalu-
ating the effects of blood levels of tacrolimus on acute GVHD after
BMT from unrelated donor in a prophylaxis regimen consisting of
tacrolimus and methotrexate. Patients/Methods: Patients under-
going BMT from unrelated donor for hematological diseases in
Keio University Hospital were eligible. Tacrolimus was given at an
initial dose of 0.03 mg/kg by continuous intravenous infusion from
day 1, and its dose was adjusted to maintain its whole blood level
at 15–20 ng/ml. MTX was given at a dose of 15 mg/m2 on day 1,
and 10 mg/m2 on days 3 and 6, and additionally on day 11 if
possible. Results: Forty-four patients (median age: 41 years old)
were evaluable. Conditioning regimens were myeloablative in 38
and reduced intensity in 6 patients. HLA compatibility was sero-
logically/genotypically matched in 29, and mismatched in 15 pa-
tients, including serologically mismatched in 2 patients. Of the 44
patients, 41 patients (93.2%) achieved mean blood level 15–20
ng/ml in the ﬁrst week (day 0–7), 34 patients (77.3%) in the second
week (day 8–14), and 35 patients (79.4%) in the third week (day
15–21) post-transplant. Eighteen (41%) patients developed grades
II–IV acute GVHD, and only 3 patients (6.8%) developed grades
III–IV acute GVHD. HLA mismatch and blood level of tacrolimus
(mean concentration  15 ng/ml) in the second week post-trans-
plant were statistically identiﬁed as risk factors for developing
grades II–IV acute GVHD, while patient or donor age, MTX on
day 11, and blood levels of tacrolimus in other post-transplant
periods did not affect the incidence of acute GVHD. No serious
complications resulting in discontinuation of tacrolimus were ob-
served. Conclusions: Tacrolimus combined with methotrexate
could effectively prevent the development of acute GVHD, par-
ticularly severe acute GVHD, after BMT from unrelated donor by
maintaining its blood level above 15 ng/ml with strict monitoring
and dose adjustment.
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DELAYED GCV-MEDIATED ABLATION OF 
CD34-tk TRANSDUCED AND
SELECTED MURINE T CELLS PRESERVES GVL ACTIVITY WHILE MITI-
GATING GVHD
Rettig, M.P.1, Ritchey, J.K.1, Prior, J.L.1, Piwnica-Worms, D.1,
Bonyhadi, M.L.2, DiPersio, J.F.1 1. Washington University School of
Medicine, St. Louis, MO; 2. Xcyte Therapies, Inc., Seattle, WA.
We and others have previously demonstrated that delayed ad-
ministration of the prodrug ganciclovir (GCV) protects mice from
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